Table 1.
Patient characteristics
| Patient code | Tumor type | NY-ESO-1 mRNA tumor expression* | NY-ESO-1 antibody status* | Preexisting CD8+ T cell responses to NY-ESO-1 peptides | Vaccination protocol with NY-ESO-1 peptides |
|---|---|---|---|---|---|
| NW415 | Melanoma | Positive | Negative | No | LUD97-008 |
| NW886 | Melanoma | Positive | Negative | No | LUD97-008 |
| NW924 | Melanoma | Positive | Positive | Yes | LUD97-008 |
| NW1288 | Gastric | Positive | Positive | Yes | None |
| NW1307 | Schwannoma | Positive | Positive | Yes | None |
| 109/ANS | Melanoma | Positive | Negative | No | LUD97-012 |
| PI-E01 | NSCLC | Positive | Negative | No | LUD00-019 |
| ES-E03 | NSCLC | Positive | Negative | No | LUD00-019 |
NSCLC, non small cell lung cancer.
*
NY-ESO-1 mRNA tumor expression and serum antibody detected as described (10).